Group 1 - The core point of the article is that Maipu Medical plans to acquire 100% equity of Yijie Medical through a combination of share issuance and cash payment, aiming to expand its product offerings in the neurosurgery field [1][2] - Maipu Medical is the only company in China that offers a comprehensive range of implantable medical devices for neurosurgery, including artificial dura mater patches and absorbable regenerated oxidized cellulose [1] - Yijie Medical specializes in providing minimally invasive interventional solutions for cerebrovascular diseases, with 11 listed products, including 8 Class III and 3 Class II medical devices, and has obtained 2 FDA registrations [2] Group 2 - The acquisition is expected to enhance Maipu Medical's product matrix and expand its market reach, leveraging existing relationships with nearly 1,000 distributors and access to around 2,000 hospitals in China [2] - The end customers of Yijie Medical's products are primarily neurology departments in hospitals, which overlap significantly with Maipu Medical's existing customer base, facilitating better marketing and sales efforts post-acquisition [2] - The transaction involves related parties, including the controlling shareholder and board members, and is subject to regulatory compliance regarding related party transactions [3]

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, along with raising supporting funds, which constitutes a related party transaction [1] Group 1: Confidentiality Measures - The company has established an insider information management system to regulate insider information management as approved in the board meeting on August 11, 2022 [1] - The company has signed confidentiality agreements with the transaction counterparties to ensure strict confidentiality regarding the transaction details, disclosing information only as required by law or necessary for the transaction [1] - The company has implemented a registration management system for insider information personnel, limiting the knowledge scope of sensitive information related to the transaction [2] Group 2: Insider Information Management - The company has created an "Insider Information Personnel Registration Form" and a "Transaction Progress Memorandum," and has reported the list of insider information personnel to the Shenzhen Stock Exchange [2] - The company has conducted multiple reminders to insider information personnel about their confidentiality obligations and responsibilities, prohibiting them from disclosing information or trading based on insider information before legal disclosure [2] - The company has taken necessary and sufficient confidentiality measures, established a strict confidentiality system, and signed confidentiality clauses with transaction counterparties, ensuring compliance with confidentiality obligations prior to legal disclosure of the transaction information [2]

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, which is not expected to constitute a major asset restructuring or a restructuring listing [1][2] Group 1 - The transaction's audit and evaluation work is not yet completed, and the valuation and transaction price of the target assets have not been determined [1] - Based on preliminary calculations using financial data from both the listed company and the target company, the transaction is expected not to meet the standards for major asset restructuring as defined by the relevant regulations [1] - The company will provide a detailed analysis and disclosure regarding the determination of whether the transaction constitutes a major asset restructuring in the restructuring report [1] Group 2 - The controlling shareholder and actual controller of the listed company will remain Yuan Yuyu before and after the transaction [2] - There has been no change in control of the listed company in the past 36 months, and this transaction will not lead to a change in control, thus not constituting a restructuring listing as per the regulations [2]

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, which is deemed compliant with the relevant regulations of the Major Asset Restructuring Management Measures for Listed Companies [1][2]. Group 1 - The restructuring meets the requirements of Article 11 of the Major Asset Restructuring Management Measures, ensuring that the asset valuation is fair and does not harm the legitimate rights and interests of the company and its shareholders [1]. - The company confirms that there are no legal obstacles to the transfer of assets prior to the transaction, and it does not involve the handling of related debts and liabilities [1]. - The company will maintain independence in personnel, assets, finance, institutions, and business after the restructuring, in accordance with the relevant regulations of the China Securities Regulatory Commission [1]. Group 2 - The restructuring complies with Article 43 of the Major Asset Restructuring Management Measures, ensuring that there are no ongoing investigations or violations of laws that could affect the transaction [2]. - The transaction is expected to enhance the quality of the company's assets and strengthen its ongoing operational capabilities without causing significant adverse changes to its financial status [2]. - The company will ensure that the transaction can be completed within the agreed timeframe, provided that all legal procedures and prerequisites are appropriately fulfilled [2]. Group 3 - The restructuring aligns with Article 44 of the Major Asset Restructuring Management Measures, promoting a diversified product matrix and preventing significant adverse impacts from competition or unfair related transactions [2].

Core Viewpoint - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is planning a major asset restructuring involving the acquisition of 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of share issuance and cash payment, along with fundraising for related transactions [2]. Shareholding Situation - As of May 21, 2025, the top ten shareholders of the company hold only ordinary shares, with specific names and shareholding ratios disclosed [3]. - The top ten circulating shareholders also hold only ordinary shares, with their respective shareholding quantities and proportions provided [3][5]. Shareholder Details - The top shareholder is Beijing Fengyan Investment Management Co., Ltd. - Beijing Fengyan Ruiying No. 3 Private Securities Investment Fund, holding a significant number of shares [3]. - Other notable shareholders include China Industrial and Commercial Bank - China Europe Medical Health Mixed Securities Investment Fund and Huatai Securities Asset Management [3]. Documentation - The shareholder list is based on the records issued by China Securities Depository and Clearing Co., Ltd. [5].

Group 1 - The company plans to issue shares and pay cash to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. and raise supporting funds, which is referred to as "this transaction" [1] - To ensure fair information disclosure and protect investor interests, the company has applied for a stock suspension starting from May 22, 2025 [1] - The cumulative price change of the company's stock in the 20 trading days prior to the suspension was 12.27% after excluding the impact of the broader market index (399006.SZ) and 14.01% after excluding the impact of the industry index (801150.SL) [1] Group 2 - The stock price did not experience abnormal fluctuations, as the cumulative price change did not exceed 20% in the 20 trading days before the suspension [1]

Meeting Overview - The third session of the Supervisory Board held its ninth meeting on June 5, 2025, with all three supervisors present, and the meeting was deemed legally valid [3][4][5]. Resolutions Passed - The Supervisory Board approved the proposal for the company to issue shares and pay cash to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. and raise matching funds [6][7]. - The transaction involves multiple parties, including Guangzhou Zexin Medical Technology Co., Ltd. and several investment partnerships [6][7]. - The voting results for all resolutions were unanimous, with 3 votes in favor and no votes against or abstentions [13][17][28]. Transaction Details - The acquisition will be executed through a combination of share issuance and cash payment, with the cash portion intended for transaction costs and working capital [6][14]. - The share issuance price is set at 41.40 RMB per share, which is not less than 80% of the average trading price over the previous 120 trading days [9][31]. - The total number of shares to be issued will be determined after the final transaction price is established [10][14]. Related Party Transactions - The transaction is classified as a related party transaction, as some of the parties involved are controlled by the company's actual controller, Yuan Yuyu [17][18]. - The company confirmed that the transaction does not constitute a major asset restructuring and will not change the control of the company [17][18]. Compliance and Regulatory Aspects - The company has ensured compliance with relevant laws and regulations, including the Company Law and Securities Law, regarding the transaction [5][26]. - The transaction is expected to enhance the company's operational capabilities and will not adversely affect its financial condition [26][28]. Financial Arrangements - The matching funds raised will not exceed 100% of the transaction price and will be used for cash payments, intermediary fees, and working capital [14][15]. - The lock-up period for newly issued shares will be 36 months for major shareholders and 12 months for other parties involved in the transaction [10][11]. Asset Evaluation - The transaction price will be based on an evaluation report from a qualified asset appraisal agency, ensuring fair pricing [7][26]. - The company will continue to maintain its independence and operational integrity post-transaction [26][28].

证券代码：301033 证券简称：迈普医学 公告编号：2025-037 广州迈普再生医学科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 关于暂不召开股东会的公告 公司于 2025 年 6 月 5 日召开了第三届董事会第十次会议及第三 届监事会第九次会议，审议通过了《关于公司发行股份及支付现金购 买资产并募集配套资金暨关联交易方案的议案》等本次交易相关议案， 具 体 内 容 详 见 公 司 于 2025 年 6 月 6 日 刊 登 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的相关公告。 根据《上市公司重大资产重组管理办法》《上市公司证券发行注 册管理办法》《上市公司监管指引第 9 号——上市公司筹划和实施重 大资产重组的监管要求》《公开发行证券的公司信息披露内容与格式 准则第 26 号——上市公司重大资产重组》《深圳证券交易所上市公 司重大资产重组审核规则》等相关法律法规和规范性文件的要求，本 次交易尚需深圳证券交易所审核通过及中国证券监督管理委员会同 意注册后方可实施。 广州迈普再生医学科技股份有限公司（以 ...

广州迈普再生医学科技股份有限公司董事会 关于本次交易符合《上市公司重大资产重组管理办法》 第十一条、第四十三条及第四十四条规定的说明 广州迈普再生医学科技股份有限公司（以下简称"公司"）拟筹 划发行股份及支付现金的方式收购广州易介医疗科技有限公司 100% 股权并募集配套资金暨关联交易事项（以下简称"本次交易"）。 6、本次交易不会改变上市公司现有的业务、资产、财务、人员、 机构等方面与实际控制人及其关联人的独立性，符合中国证监会关于 上市公司独立性的相关规定。本次交易完成后，上市公司将严格按照 《上市公司治理准则》等法律法规的要求，保证上市公司在人员、资 产、财务、机构、业务等方面的独立性，规范上市公司运作； 7、本次交易前，上市公司已按照《公司法》《证券法》及中国证 监会的有关要求设立了相应的法人治理结构。本次交易完成后，上市 公司将继续严格按照法律、法规和规范性文件及《公司章程》的要求 规范运作，完善健全已建立的法人治理结构。 二、本次重组符合《上市公司重大资产重组管理办法》第四十三 条的规定 公司董事会对于本次交易是否符合《上市公司重大资产重组管理 办法》（以下简称《重组管理办法》）第十一条、第四十三 ...

广州迈普再生医学科技股份有限公司董事会 关于本次交易前 12 个月内购买、出售资产情况的说明 广州迈普再生医学科技股份有限公司 董事会 2025 年 6 月 6 日 广州迈普再生医学科技股份有限公司（以下简称"公司"）拟筹 划发行股份及支付现金购买广州易介医疗科技有限公司 100%股权并 募集配套资金暨关联交易事项（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》第十四条的有关规定： "上市公司在十二个月内连续对同一或者相关资产进行购买、出售的， 以其累计数分别计算相应数额。已按照本办法的规定编制并披露重大 资产重组报告书的资产交易行为，无须纳入累计计算的范围。中国证 监会对本办法第十三条第一款规定的重大资产重组的累计期限和范 围另有规定的，从其规定。交易标的资产属于同一交易方所有或者控 制，或者属于相同或者相近的业务范围，或者中国证监会认定的其他 情形下，可以认定为同一或者相关资产。" 截至本公告披露日，在公司审议本次交易的董事会召开日前 12 个月内，公司未发生与本次交易相关的购买、出售资产的交易行为， 不存在需要纳入累计计算范围的情形。 特此说明。 ...